#Amgen

Fazen Capital

@fazencapital.bsky.social

1 day ago

Amgen Posts Positive Results for Subcutaneous Tepezza Amgen's Apr 6, 2026 topline shows positive late-stage results for subcutaneous Tepezza; company filings cite ~ $1.2bn Tepezza sales in 2023, accelerating potential market access change.

Amgen Posts Positive Results for Subcutaneous Tepezza: Amgen's Apr 6, 2026 topline shows positive late-stage results for subcutaneous Tepezza; company filings cite ~ $1.2bn Tepezza sales in 2023, accelerating potential… 👈 Read full analysis #Amgen #Tepezza #Pharmaceuticals #Biotech #ClinicalTrials

Thiard News@F4F

@newsen.bsky.social

2 days ago

Amgen Announces Successful Phase 3 Results for TEPEZZA in Thyroid Eye Disease Treatment Amgen has revealed optimistic topline results from a Phase 3 trial demonstrating the efficacy of TEPEZZA for thyroid eye disease via subcutaneous administration.

Amgen Announces Successful Phase 3 Results for TEPEZZA in Thyroid Eye Disease Treatment #United_States #Amgen #Thousand_Oaks #Thyroid_Eye_Disease #TEPEZZA

@pharmalot.bsky.social

1 week ago

Pharmalittle: We're reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more The FDA is moving toward allowing compounding pharmacies to produce injectable peptides that were banned over significant safety concerns

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more news.. statnews.com/pharmalot/20... #pharma #FDA #compounding #Iran #obesity #Amgen #Bayer #NovoNordisk

pharmaphorum

@pharmaphorum.bsky.social

1 week ago

FDA points to liver injury with Amgen's Tavneos The FDA raises the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

The #FDA has ramped up the pressure on #Amgen to #withdraw #Tavneos for a rare #vasculitis condition from the market, with a report saying it has identified cases of serious #liverinjury – including deaths – among people taking the drug.

ZettaWire

@zettawire.com

1 week ago

The US FDA has linked the Amgen-manufactured drug Tavneos to serious liver injuries. Eight deaths have been reported in connection with the medication, according to the agency's statement on Tuesday. #US #Tavneos #Amgen

Thiard News@F4F

@newsen.bsky.social

1 week ago

Amgen's Repatha® Successfully Reduces Cardiovascular Event Risks in Patients with Diabetes Recent findings reveal that Repatha® can lower the risk of major cardiovascular events by 31% in high-risk diabetic patients without significant atherosclerosis, marking a significant breakthrough in preventive care.

Amgen's Repatha® Successfully Reduces Cardiovascular Event Risks in Patients with Diabetes #USA #Amgen #Thousand_Oaks #Repatha #CVS

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen to Showcase Innovations at the 2026 Global Healthcare Conference Amgen is set to participate in the upcoming Leerink Partners Global Healthcare Conference on March 11, 2026, sharing insights on their latest healthcare innovations.

Amgen to Showcase Innovations at the 2026 Global Healthcare Conference #United_States #Innovation #Healthcare_Conference #Amgen #Thousand_Oaks

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen Declares $2.52 Dividend for the Second Quarter of 2026 Amgen's Board has declared a $2.52 per share dividend for Q2 2026, reflecting the company's strong performance and commitment to shareholders.

Amgen Declares $2.52 Dividend for the Second Quarter of 2026 #USA #Dividend #biotechnology #Amgen #Thousand_Oaks

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen Set to Showcase Innovations at 46th Annual TD Cowen Health Care Conference Amgen will present at the TD Cowen Health Care Conference on March 2, 2026. Key executives will share insights on the company's advancements in healthcare technologies.

Amgen Set to Showcase Innovations at 46th Annual TD Cowen Health Care Conference #United_States #Amgen #Thousand_Oaks #Health_Care #TD_Cowen

Thiard News@F4F

@newsen.bsky.social

1 month ago

EU Approves Amgen's UPLIZNA® for Treating Generalized Myasthenia Gravis Amgen's UPLIZNA receives EU approval as a treatment for Generalized Myasthenia Gravis, providing new hope for patients with this chronic autoimmune condition.

EU Approves Amgen's UPLIZNA® for Treating Generalized Myasthenia Gravis #None #Amgen #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen's UPLIZNA® Receives European Commission Approval for Myasthenia Gravis Treatment Amgen's innovative drug, UPLIZNA®, has been granted EU approval as a crucial treatment for generalized myasthenia gravis patients, with promising results.

Amgen's UPLIZNA® Receives European Commission Approval for Myasthenia Gravis Treatment #None #Amgen #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen's UPLIZNA® Approved by European Commission for Treatment of Myasthenia Gravis The European Commission has granted approval for Amgen's UPLIZNA® as an additional treatment for generalized myasthenia gravis, offering hope to patients.

Amgen's UPLIZNA® Approved by European Commission for Treatment of Myasthenia Gravis #Amgen #Thousand_Oaks #Czech_Republic #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

1 month ago

European Commission Approves Amgen's UPLIZNA® for Treating Myasthenia Gravis Amgen has announced the European Commission's approval of UPLIZNA® for general myasthenia gravis, enabling better treatment options and improved patient care.

European Commission Approves Amgen's UPLIZNA® for Treating Myasthenia Gravis #None #Amgen #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

1 month ago

European Commission Approves Amgen's UPLIZNA® for Treating Generalized Myasthenia Gravis The European Commission has granted approval for Amgen's UPLIZNA® as an adjunct therapy for adults suffering from generalized myasthenia gravis. This marks a significant milestone in targeted treatment options.

European Commission Approves Amgen's UPLIZNA® for Treating Generalized Myasthenia Gravis #None #Amgen #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

1 month ago

European Commission Approves Amgen's UPLIZNA® for Treatment of Generalized Myasthenia Gravis The European Commission has granted approval for Amgen's UPLIZNA® as a complementary treatment for adult patients with generalized myasthenia gravis, offering a new hope for better disease management.

European Commission Approves Amgen's UPLIZNA® for Treatment of Generalized Myasthenia Gravis #None #Amgen #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen's UPLIZNA® Secures European Approval for Myasthenia Gravis Treatment Amgen's UPLIZNA® gains European Commission approval as an innovative treatment for generalized myasthenia gravis, providing long-term disease control.

Amgen's UPLIZNA® Secures European Approval for Myasthenia Gravis Treatment #United_Kingdom #Amgen #Thousand_Oaks #GMG #UPLIZNA®

@pharmalot.bsky.social

2 months ago

Pharmalittle: We're reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more Based on ads released in advance of the Super Bowl, little has changed in the eyes of the pharma industry since the FDA began a "crackdown" on drug marketing

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more news.. statnews.com/pharmalot/20... #pharma #SuperBowl #autism #layoffs #FDA #FTC #PBM #Cigna #Amgen

pharmaphorum

@pharmaphorum.bsky.social

2 months ago

#Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated #vasculitis from the US market. #ANCAAssociatedVasculitis
#RareDisease #pharmanews #lifesciences pharmaphorum.com/news/amgen-b...

Thiard News@F4F

@newsen.bsky.social

2 months ago

Amgen Reports Robust Financial Growth for 2025: Key Highlights from Fourth Quarter Results Amgen showcases impressive 2025 financial results, with double-digit revenue growth and record sales across multiple products, indicating strong market performance.

Amgen Reports Robust Financial Growth for 2025: Key Highlights from Fourth Quarter Results #United_States #financial_results #revenue_growth #Amgen #Thousand_Oaks

DengYue Medicine

@dengyuemedicine.bsky.social

2 months ago

Amgen/UCB: Romosozumab aprobado para su comercialización por la NMPA en China

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Romosozumab #Osteoporosis #Postmenopáusica #NMPA #Amgen #UCB #Biológicos #SaludÓsea #AprobaciónRegulatoria

True Story Golden

@truestorygolden.bsky.social

2 months ago

#Amgen... #Novartis claims to donate cures for free... Watch their multi-drug treatment sold on the black market...

Ralf Reski

@reskilab.bsky.social

2 months ago

Amgen wählt Disco Pharma als Partner in Millionendeal Das neue Jahr startet bei der Kölner Disco Pharma wie das alte endete: mit einer schlagzeilenträchtigen Meldung. Vor dem Jahreswechsel war es ein beachtlicher Aufschlag zur Finanzierungsrunde gewesen,...

Amgen wählt Disco Pharma als Partner in Millionendeal
Letztes Jahr war es ein beachtlicher Aufschlag zur Finanzierungsrunde, nun folgt eine beachtliche Partnerschaft mit dem US Biotech-Pionier #Amgen, die bis zu 618 Mio. US-Dollar wert werden kann.
transkript.de/artikel/2026...

Thiard News@F4F

@newsen.bsky.social

2 months ago

Ro and Amgen Join Forces to Enhance Patient Access to GLP-1 Treatments Ro teams up with Amgen to explore real-world challenges patients face in accessing GLP-1 treatments. This collaboration aims to improve care and accessibility.

Ro and Amgen Join Forces to Enhance Patient Access to GLP-1 Treatments #USA #New_York #Amgen #GLP-1 #Ro

@emergingtechnews.bsky.social

2 months ago

Acquisitions: #Amgen > #DarkBlueTherapeutics; #AxioAero > #AirwayAerospace; #AxiomGRC > #AssurancePoint; #Cvent > #Goldcast; #flexera > #ProsperOps; #Flutterwave > #Mono; #FormativGroup > #EonCollective; #Postman > #Fern; #RedHat > #Chatterbox; #UserTesting > #UserInterviews

Centro Nacional de Biotecnología (CNB)

@cnb-csic.bsky.social

2 months ago

📣 Atención profesionales del periodismo y la divulgación científica 👀

Junto a #Amgen lanzamos los 1º Premios de Periodismo y Divulgación sobre Genética.

📅 Envía tu trabajo del 7/01 al 27/02/2026.

ℹ️ Consulta las bases y más información:
https://f.mtr.cool/wodlhfbcdm

Thiard News@F4F

@newsen.bsky.social

3 months ago

Amgen's CEO to Address Key Innovations at the Upcoming 2026 J.P. Morgan Healthcare Conference On January 12, 2026, Amgen will showcase its latest innovations at the J.P. Morgan Healthcare Conference, led by CEO Robert A. Bradway, via an internet livestream.

Amgen's CEO to Address Key Innovations at the Upcoming 2026 J.P. Morgan Healthcare Conference #United_States #Healthcare_Conference #J.P._Morgan #Amgen #Thousand_Oaks

@pharmalot.bsky.social

3 months ago

Pharmalittle: We're reading about an Eli Lilly deal, an Amgen acquisition, and much more Eli Lilly is in advanced talks to acquire Ventyx Biosciences, which is developing pills for autoimmune conditions, for more than $1 billion

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an Eli Lilly deal, an Amgen acquisition, and much more news.. statnews.com/pharmalot/20... #pharma #biotech #obesity #Lilly #Monsanto #Covid #Amgen #GSK

www.cyclisme-dopage.com

@cyclisme-dopage.com

3 months ago

La saga de l'EPO La saga de l'EPO...

Il y a 12 ans : La saga de l'EPO www.cyclisme-dopage.com/dossierdefon... #cyclisme #dopage #EPO #AMGEN #Aranesp

🆃op🅽ews EN 🍋‍🟩 Verified. Not Amplified.

@toppnews.bsky.social

3 months ago

→ zum Artikel

#Amgen #cancer #UK

pharmaphorum

@pharmaphorum.bsky.social

3 months ago

Amgen inks $840m takeover of UK's Dark Blue Therapeutics Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

In what is thought to be the first major pharma #M&A deal of the year, #Amgen has bought Oxford, UK-based #biotech #DarkBlueTherapeutics (DBT), which specialises in #cancer therapies.

pharmaphorum.com/news/amgen-i...